KDM6B and posterior cortical atrophy: In addition, GSK-J4, an inhibitor of KDM6B, could suppress the vitality and progression of PCa and cooperate with MDV3100 to suppress CRPC and MDV3100-resistant CRPC, it can serve as a promising therapeutic for the treatment of PCa.